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Background: The frequency, characteristics and impact of acute exacerbations in patients
with alpha-1 antitrypsin deficiency (AATD) and COPD who are on intravenous alpha-1 antitryp-
sin augmentation therapy have not been described.
Methods: 922 subjects with AATD and COPD on augmentation therapy (mean age 54.5 years)
were followed with monthly telephone surveys to record exacerbation characteristics, as well
as healthcare resource utilization and health-related quality of life (HRQoL). Exacerbations
were defined by symptom-based and healthcare resource utilization (HRU) criteria.
Results: During the 1-year follow-up, 91.5% of participants experienced at least one exacerba-
tion (mean 2.4 exacerbations per subject, median 2, and mean duration 17 days per episode,
regardless of the definition used). Most exacerbations were categorized as severe by symptoms
and moderate by HRU criteria. Subjects who had 3 or more exacerbations (48.6%) were
younger, had higher medication use and had higher tobacco consumption compared with
subjects with less exacerbations. Subjects with frequent exacerbations had the worst baseline
HRQoL scores, as well as more physician visits, emergency room visits, and hospitalizations.
Although most subjects received augmentation therapy on a weekly basis, other infusion
schedules were more commonly observed in subjects with fewer exacerbations.sin deficiency; COPD, chronic Obstructive Pulmonary Disease; FEV1, forced expiratory volume in 1 s;
, healthcare resource utilization; HRQoL, health-related quality of life; SGRQ, St. George’s Respi-
rm-36.
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Exacerbations in alpha-1 antitrypsin deficiency 1533Conclusion: COPD exacerbations occur frequently and are associated with significant disease
burden in subjects with AATD receiving augmentation therapy.
ª 2009 Elsevier Ltd. All rights reserved.Figure 1 Diagram showing study enrollment process.Introduction
It is widely recognized that acute exacerbations of chronic
obstructive pulmonary disease (COPD) play a central role in
COPD-related morbidity and mortality.1 Exacerbations are
associated with marked physiologic deterioration that may
affect disease progression by accelerating reductions in
forced expiratory volume in 1 s (FEV1)
2,3 and have a signifi-
cant negative effect on the individual’s health-related
quality of life (HRQoL).4,5 The profound impact that COPD
exacerbations have on individuals, along with the high
healthcare costs associated with them,6 has led to a need
for early recognition of patients at risk of frequent
exacerbations.
Subjects with severe alpha-1 antitrypsin deficiency
(AATD) have decreased lung protection against the effects
of neutrophil elastase and susceptible subjects are at risk
for early-onset COPD, with most affected individuals being
diagnosed around the age 44e45 years.7,8 During acute
exacerbations, the excess neutrophil burden is significantly
higher in AATD than in non-AATD COPD subjects.9 Whether
this translates into more frequent and/or more severe
exacerbations is not known, as only a few studies have
addressed exacerbations in this specific population. In the
National Heart, Lung, and Blood Institute (NHLBI) AATD
Registry Study, ‘‘chest illness’’ that kept patients off work,
indoors at home, or in bed in the prior 3 years was self-
reported by 68% of the 1129 patients followed.10 In a more
recent study of 265 subjects with AATD, 54% of subjects
recalled having at least one COPD exacerbation during the
prior year.11
Therapy for subjects with lung disease from AATD
includes the usual treatments for COPD with the addition of
specific intravenous augmentation therapy with purified
alpha-1 antitrypsin.12 Augmentation therapy has been
shown to decrease bronchial inflammatory markers in these
individuals13 and a report based on subjective data sug-
gested that this therapy may decrease the frequency of
exacerbations.14 Since the incidence and impact of acute
exacerbation episodes in individuals with AATD who receive
augmentation therapy have not previously described, we
report here the characteristics of acute exacerbations in
a large cohort of individuals with AATD and COPD who
receive augmentation therapy and characterize the
subgroup of subjects who suffer the most exacerbations.
Methods
The exacerbation data analyzed here belongs to a 12-month
non-interventional baseline follow-up of 922 subjects
with AATD, who participated in a project to assess the
impact of a disease management program. From the 1062
participants who started the baseline survey, 140 were
excluded for the reasons shown in Fig. 1. All subjects were
receiving augmentation therapy for AATD (Prolastin,Talecris Biotherapeutics, Research Triangle Park, NC) and
were members of AlphaNet, a not-for-profit health
management company that coordinates services for
patients with AATD, including the distribution of augmen-
tation therapy.
Study design
The study design and informed consent process were
approved by the University of Miami’s Institutional Review
Board and have been described previously.7,15 In brief,
since participants resided throughout the United States
data were collected via phone interviews. Experienced
surveyors (Qessential Medical Market Research LLC, Exeter,
NH) collected initial baseline clinical and demographic data
and obtained HRQoL information with the St. George’s
Respiratory Questionnaire (SGRQ)16 at 0 and 12 months and
the Short-Form-36 (SF-36) at baseline.17 Twelve additional
standardized monthly phone surveys were undertaken by
regionally based AlphaNet coordinators to collect data on
COPD exacerbations and healthcare resource utilization
(HRU). All survey results were entered directly into a secure
database via an encrypted Web-based system at the time
they were obtained.
Definition of exacerbations
The surveys included questions that directly assessed
exacerbations according to 2 different criteria: symptom-
based and HRU-based. The symptom-based criteria,
proposed by Anthonisen et al.,18 use a combination of three
cardinal exacerbation symptoms (increased dyspnea,
sputum volume and sputum purulence) and categorize
exacerbations as severe if the patient has all the 3 symp-
toms, moderate if only two are present, and mild if the
patient has only one of the above symptoms, combined
1534 M.A. Campos et al.with cough, wheeze, or symptoms of an upper respiratory
tract infection. The HRU-based criteria are a consensus
definition by an expert panel and define an exacerbation as
‘‘a sustained worsening of the patient’s condition from the
stable state and beyond normal day-to-day variation, that
is acute in onset and necessitates a change in regular
medication’’.19 By this criteria, an exacerbation is catego-
rized as mild if it can be managed in the normal environ-
ment with an increase in the usual medication, moderate if
it needs additional medical assistance (physician contact or
emergency room visits), and severe if it requires hospital-
ization. Duration of exacerbations was recorded by asking
the number of days with symptoms during the prior month.
To avoid overestimation of exacerbation frequency,
subjects reporting exacerbation symptoms on the prior 30
days were asked if they were experiencing symptoms at the
time of the phone interview. If their answer was positive,
and they reported exacerbation symptoms in the following
survey (month), both were clustered together as one
exacerbation (and duration was recorded from the second
survey).
Study subjects
All study participants were diagnosed with AATD by their
own physicians and were placed on augmentation therapy
because of symptomatic obstructive lung disease. The
mean age of participants was 54.5 9.6 years and their
mean age at diagnosis of AATD was 45.5 9.5 years. The
cohort was 52% male and 98% Caucasian. Most were ex-
smokers (82%). There were 7 subjects that reported active
smoking (0.07%) when entering the study, but all quit during
the study year after intensive counseling and encourage-
ment by the study coordinators. Participants were asked to
send a copy of their genotype/phenotype at diagnosis (94%
were genotype ZZ) and spirometry results if performed
during the study year while in a stable clinical state. We
had to rely on spirometry tests performed by each indi-
vidual’s healthcare provider since they were geographically
spread throughout the country.
The spirometry data were used only for COPD staging
purposes using the Global Initiative for COPD (GOLD) cri-
teria.1The mean FEV1 of the 658 subjects (67% of the total)
with available spirometry results was 1.2 0.6 L and their
mean % predicted post-bronchodilator FEV1 was 39.5 19.3.
The clinical characteristics of individuals with unavailable
spirometry results did not differ clinically from the whole
group (Table 1).
Analysis
Data were analyzed using SAS version 9.1.3 for Windows
(SAS Institute, Inc., Cary, NC). Descriptive statistics are
displayed as the mean and standard deviation, or
percentage. Chi-square test was used to compare propor-
tions, and Student’s t test and analysis of variance (ANOVA)
with Bonferroni test to compare means between groups
defined by sociodemographic or clinical characteristics.
Variables that did not have a normal distribution were
compared with the ManneWhitney U test. All tests were
performed two-sided with a significance level of 5%.Results
Characteristics of exacerbations
During the 1-year follow-up, 844 subjects (91.5%) reported
at least one acute disease exacerbation. Most exacerba-
tions were categorized as severe by the symptom-based
criteria and moderate by the HRU-based criteria (Table 2).
With either criterion, the median number of exacerbations
was two per patient. Most exacerbations lasted approxi-
mately 2 weeks (mean 17 days, median 15 days) and in the
majority of cases (> 85%) lasted less than 29 days
(Fig. 2A). Exacerbations were reported throughout the
year, with at least 28e30% of the subjects reporting an
exacerbation in any given calendar month, but mostly
during the winter months (Fig. 2B).
Subjects with COPD stage I and II (nZ 128) had statis-
tically significantly fewer total exacerbations using either
criteria when compared with subjects with COPD stage III
(nZ 164) or stage IV (nZ 366) (Fig. 2C) and statistically
significantly shorter duration of exacerbations (mean
14.2 8.6, median 12 days) than subjects in GOLD stage III
(mean 17.8 12.3, median 15 days) and GOLD IV (mean
17.5 12.9, median 15 days).Characteristics of subjects with frequent
exacerbations
We defined subjects with frequent exacerbations those
who reported more exacerbations than the median for
the cohort (3 exacerbations per year). The clinical and
demographic characteristics of these subjects (nZ 448,
48.6%) were compared with those of subjects who had 1e2
(nZ 391; 42.4%) or no (nZ 83, 9.0%) exacerbations during
the 12-month follow-up (Table 3). Subjects with frequent
exacerbations were more likely to be women, younger,
unemployed, ex-smokers and with symptoms of chronic
bronchitis. These subjects also had higher medication
utilization and were more likely to be on long-term oxygen
therapy. Although no differences were observed among
the 3 groups regarding duration or weekly dose of
augmentation therapy (not shown), subjects with frequent
exacerbations were more likely to be receiving weekly
doses. Baseline HRQoL scores were also significantly worse
for subjects with frequent exacerbations throughout
all the domains of both the SGRQ and SF-36 surveys
(Table 3). Over the year, the total SGRQ scores decreased
(improved) in all three groups, but not by a clinically
significant extent (more than four points). Although there
was a trend for less improvement in SGRQ total scores in
the frequent exacerbation group, the difference was not
statistically significant (not shown).
During the 12-month follow-up, 357 subjects (38.7%) had
at least one unscheduled physician visit (median 2), 171
subjects (18.5%) visited an emergency room (ER) at least
once (median 1) and 105 subjects (11.3%) were hospitalized
at least once (median 1). Subjects with frequent exacer-
bations experienced significantly more of these adverse
COPD outcomes compared with subjects in the other 2
groups (Table 4).
Table 1 Baseline patient characteristics.a
All subjects Subjects with
available
pulmonary
function tests
Subjects
without
available
pulmonary
function tests
p-Valueb
Number of subjects 922 658 264
Male sex 52.6% 51.8% 53.6% NS
Age (years) 54.5 9.6 55.1 9.6 52.7 9.6 <0.05
Marital status (has partner) 73.5% 74.1% 72.2% NS
Live with children at home 19.7% 19.6% 19.9% NS
Employed 34.4% 34.2% 35.6% NS
Tobacco history
Ever smoked (>10 pack-years) 82.1% 81.2% 82.9% NS
Total pack-years 23.5 14.8 23.4 14.9 23.6 14.5 NS
Passive smoking exposure 80.8% 80.0% 82.4% NS
Age AATD was diagnosed (years) 45.5 9.5 46.5 9.4 43.5 9.9 <0.05
Years symptomatic before AATD diagnosis 15.1 9.2 14.4 9.5 15.4 9.4 NS
Years on augmentation therapy 6.6 4.3 6.7 4.1 6.4 4.3 NS
Dose of augmentation therapy (mg/kg/week) 62.2 9.7 62.4 9.5 61.9 9.1 NS
SGRQ Total Score 48.1 18.4 47.6 18.7 50.1 18.2 <0.05
SF-36 Physical Composite Score 35.3 9.7 35.6 9.2 35.1 9.9 NS
SF-36 Mental Composite Score 52.1 11.7 51.8 12.1 52.5 11.3 NS
a Values represent percentages or mean SD.
b Differences between subjects with available and unavailable spirometry results.
Table 2 Reported exacerbations over 1-year.
Symptom-
based criteria
HRU-based criteria
Exacerbations per subject per year
Median, range 2 (0e6) 2 (0e6)
All exacerbations,
mean SD
2.44 1.3 2.45 1.3
Mild exacerbations,
mean SD
0.55 0.8 0.42 0.7
Moderate exacerbations,
mean SD
0.68 0.8 1.78 1.2
Severe exacerbations,
mean SD
1.22 1.2 0.25 0.4
Duration of exacerbations (days per episode)
All exacerbations,
mean SD
17.4 11.4 17.8 12.0
Mild exacerbations,
mean SD
14.4 11.8 13.4 10.4
Moderate exacerbations,
mean SD
15.5 13.7 17.9 14.1
Severe exacerbations,
mean SD
17.5 14.0 20.9 18.9
Number of subjects with at least one exacerbation per year
At least one mild
exacerbation, n (%)
391 (40.1) 268 (27.5)
At least one moderate
exacerbation, n (%)
467 (47.9) 820 (84.1)
At least one severe
exacerbation, n (%)
624 (64.0) 229 (23.5)
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therapy
All participants received augmentation therapy during the
study period, but with variable infusion schedules: 553
(60%) received weekly infusions, 299 (32.4%) received
infusions every 2 weeks, and 70 (7.6%) received monthly
infusions. Regardless of the infusion schedule, there were
no significant differences in dose (mean 62.2 9.7 mg/kg/
week) or length of augmentation therapy (mean 6.51 4.4
years). Although most subjects received the recommended
weekly infusion schedule, alternate schedules were more
likely observed among subjects with less frequent exacer-
bations during follow-up (Fig. 3).
Discussion
Although based mostly on observational data, augmentation
therapy with purified alpha-1 antitrypsin preparations is
generally recommended for all symptomatic subjects with
AATD and documented lung disease.12 The effect in slowing
lung function decline appears to be more effective in
subjects with moderate impairment of lung function (FEV1
between 30% and 65% predicted).20,21 Although it is believed
that it may affect exacerbation frequency,14 the true effect
of augmentation therapy on the natural history of acute
exacerbations is unknown.We report here the frequency and
impact of acute exacerbations of COPD in a large cohort of
subjects with AATD on augmentation therapy.
Probably the most striking finding of our study is the
documentation of a very high prevalence of exacerbations
in this population (>85% of subjects, mean 2.4 episodes per
Figure 2 Chronic obstructive pulmonary disease exacerbations in subjects with alpha-1 antitrypsin (AAT) deficiency, using both
symptom-based and HRU-based criteria. A) Duration of exacerbation in days according to exacerbation severity. B) Monthly
variation of exacerbation frequency plotted by calendar year. C) Severity of exacerbations according to Global Initiative for
Chronic Obstructive Lung Disease (GOLD) stage (NZ 658 subjects). Bars represent standard deviation. *p< 0.05 for GOLD stage IeII
vs. stage III and IV. **p< 0.05 for GOLD stage IeII vs. stage IV.
1536 M.A. Campos et al.year). The reported frequency of exacerbations in a U.K.
cohort of subjects with AATD not receiving augmentation
therapy was less,11 in which 54% of 265 subjects reported at
least one exacerbation over 1 year (mean rate 1.2 episodes
per subject per year). This difference with our report is
likely due to different methodology of data collection, in
particular recall interval (monthly vs. yearly), since a follow
study using dairy cards in the same U.K. cohort, exacerba-
tion rates increased to 5 episodes per subject per year (3
treated and 1.5 untreated).22 More frequent querying about
exacerbation symptoms in our study may have allowed us to
detect many (milder) exacerbations that will be otherwise
unrecognized. Indeed, 17% of the exacerbations evaluated
by the HRU-based criteria were categorized as mild, in other
words, exacerbations that did not require evaluation or
consultation by a healthcare provider. The annualexacerbation frequency observed in our cohort is similar to
that observed in 38 AATD subjects receiving augmentation
therapy in the recently reported EXACTLE study (2.55 2.1
episodes per subject).23 These highlights that exacerbations
in subjects with AATD are frequent despite the administra-
tion of augmentation therapy, and represent a more signifi-
cant burden than what is usually recognized.
Exacerbations in our cohort lasted approximately 15 days
per episode. Althoughnodirect comparisons canbemade, the
length is importantly different (7 days) from that reported in
other non-AATD subjects with similar lung function and mean
exacerbation rates.3 Similar longerexacerbationdurationwas
also reported in the U.K. AATD cohort not receiving augmen-
tation therapy (14e16 days).11,22 In this study, the authors
suggested that the lack of alpha-1 antitrypsin had no effect in
modulating exacerbation frequency but affected its
Table 3 Patient characteristics at baseline.a
Subjects with
No
exacerbations
over 1 year
Subjects with
1-2
exacerbations
over 1 year
Subjects With
3
exacerbations
over 1 year
ANOVA p-value
Number of subjects 83 391 448
Male sex 53.0% 59.3% 47.2% 0.01d
Age (mean SD) 56.2 9.5 54.8 9.4 53.8 9.7 <0.05b
Marital status (has partner) 73.7% 77.4% 70.8% 0.07
Currently employed 49.4% 35.2% 29.6% <0.01b,c
Live with children at home 16.9% 18.8% 22.2% 0.44
Ever smoked (>10 pack-years) 76.3% 78.5% 86.4% <0.01d
Chronic bronchitis 16.9% 24.0% 30.0% <0.01b,d
Medication use
Short-acting beta agonists 61.0% 77.3% 87.5% <0.01b,c,d
Long-acting beta agonists 45.5% 59.4% 65.6% <0.01b,c,d
Short-acting anticholinergics 50.7% 57.7% 69.4% <0.01b,d
Theophylline 14.3% 14.5% 20.2% 0.08
Inhaled corticosteroids 55.8% 64.8% 70.9% <0.01b
Systemic corticosteroids 3.9% 3.8% 7.9% 0.03d
Long-term oxygen therapy 34.2% 45.5% 52.2% <0.01b
SGRQ, mean SD
Total 37.3 17.3 44.5 16.6 52.4 16.5 <0.01b,d
Activity 57.5 23.4 64.1 21.2 71.0 20.5 <0.01b,d
Symptoms 33.1 43.5 43.0 22.1 54.0 21.4 <0.01b,d
Impacts 27.0 16.5 33.6 16.5 41.2 17.6 <0.01b,d
SF-36, mean SD
Physical composite score 40.3 10.0 36.5 9.7 33.4 8.9 <0.01b,c,d
Mental composite score 56.8 7.8 54.2 10.1 49.4 13.0 <0.01b,d
Physical functioning 35.3 11.4 32.9 10.2 29.4 9.3 <0.01b,c,d
Role-physical 46.2 10.6 40.9 10.8 36.7 10.7 <0.01b,c,d
Bodily pain 56.3 9.5 52.8 10.8 50.2 11.4 <0.01b,c,d
General health 39.1 12.1 35.3 11.9 30.5 10.7 <0.01b,c,d
Vitality 51.0 12.0 47.3 11.6 43.8 11.1 <0.01b,c,d
Social functioning 49.1 10.3 47.3 11.6 42.4 12.9 <0.01b,d
Role-emotional 52.5 6.7 48.7 10.3 43.9 13.3 <0.01b,c,d
Mental health 54.4 8.1 52.0 9.8 47.7 12.1 <0.01b,d
Definition of abbreviations: ANOVAZ analysis of variance; GOLDZGlobal Initiative for Chronic Obstructive Lung Disease; MCSZmental
component score; PCSZ physical component score; SF-36Z Short-Form-36; SGRQZ St. George’s Respiratory Questionnaire.
a Values represent percentages within each exacerbation group.
b Differences between subjects with no exacerbations vs. subjects with 3 exacerbations over 1 year.
c Differences between subjects with no exacerbations vs. subjects with 1e2 exacerbations over 1 year.
d Differences between subjects with 1e2 and 3 exacerbations over 1 year.
Exacerbations in alpha-1 antitrypsin deficiency 1537resolution time. From our findings, it appears that AATD
subjects continue to experience long exacerbation times
while receiving augmentation therapy. Duration of exacer-
bations should probably be considered as a marker ofTable 4 Healthcare resource utilization in the study cohort.a
All (%) No exacerbations in 1 year (%) 1e
Unscheduled visits 38.7 18.0 33
Emergency room visits 18.5 9.0 14
Hospitalizations 10.4 1.2 7
a Percent of subjects in each group who experienced at least one eexacerbation severity, as it adds significantly to the burden of
exacerbations.
In an Internet-based survey, 63% of 89 patients who
received augmentation therapy for more than a year2 Exacerbations in 1 year (%) 3 Exacerbations in 1 year (%)
.3 51.0
.9 23.3
.3 15.9
vent in 1 year, using symptom-based criteria.
Figure 3 Augmentation therapy infusion schedules according
to frequency of exacerbations. The proportion of subjects
receiving each infusion regimen was significantly different
between subjects with no and 3 or more exacerbations by c2
analysis.
1538 M.A. Campos et al.subjectively believed they had a reduction in the number of
lung infections since starting therapy, a subjective reduction
from 3 to 5 infections per year, to 0 to 1.14 From the currently
three different purified alpha-1 antitrypsin formulations
commercially available in the United States, there are
(indirect) suggestions that some may have different effects
on exacerbation frequency.24 In the placebo-controlled
EXACTLE study,23 augmentation therapy did not reduce total
exacerbation rates compared with placebo, but appeared to
ameliorate disease severity in a post hoc analysis. Augmen-
tation therapy decreases the inflammatory milieu in airway
secretions, as reflected by significant reduction of elastase
activity and levels of the chemoattractant leukotriene B4 in
sputum within 1 month of treatment.13 Whether this trans-
lates modulation of the natural history of exacerbations in
AATD still unknown and further studies are needed to
understand the effect of augmentation therapy on
exacerbations.
We were able to define some characteristics of the
subgroup of subjects who suffered the most exacerbations.
Consistent with other reports, these subjects were more
likely to have chronic bronchitis and worse baseline HRQoL
scores. Radiologic information to determine if chronic
bronchitis was associated with the presence of bronchiec-
tasis was unavailable to us. We also found that these indi-
viduals are more likely to have been exposed to tobacco,
which highlights the importance of tobacco exposure in
modulating the pulmonary manifestations of AATD. The
observation that younger subjects had more frequent
exacerbations may reflect an association of exacerbations
with more rapid disease progression, in which subjects with
rapid disease progression are symptomatic at an earlier
age. These younger subjects may have their disease course
modulated by the higher tobacco exposure and/or by the
effect of other modifier genes, subsequently worsened by
exacerbations. In addition, younger individuals are more
likely to be in close contact with children that may put
them at higher risk of exposure to respiratory viruses.It has been shown that weekly infusions of augmentation
therapy result in adequate ‘‘protective’’ AAT trough
levels,25 while the more ‘‘patient convenient’’ biweekly
and monthly regimens result in protective AAT levels
throughout most (85%), but not all, the interval between
infusions due to pharmacokinetic variability between indi-
viduals.26,27 No controlled studies evaluating exacerbation
rates and different infusion schedules exist. Our observa-
tion that subjects with frequent exacerbations were more
likely receiving the recommended weekly infusion sched-
ules,12 likely reflects physician and patient preferences of
more aggressive care for the most symptomatic subjects
(and vice versa).
It must be considered that the subjects in our study
received frequent follow-ups and advice as part of
a network, which may have affected exacerbation outcomes
by leading to the institutionof earlier and/ormoreaggressive
interventions. If this was the case, the true impact of acute
exacerbations may have been underestimated. Further
studies in this population can be improved with the use of
objective measurements such as diary cards, measurements
of acute changes in expiratory flow and biomarkers. Also,
randomized studies comparing different augmentation
dosages and infusion schedulesmay help assess the impact of
this form of therapy on exacerbation outcomes. Finally,
objective measures of lung function changes can provide
a broader assessment of the impact of exacerbations on the
natural history of the disease.
This study provides evidence that despite augmentation
therapy, subjects with AATD still experience high annual
exacerbation rates with profound impact on HRQoL and
HRU, and calls for improved therapies for this population.
We hope that our data will be useful for planning future
therapeutic strategies and developing preventive
interventions.
Conflict of interest statement
None of the authors have any personal or financial support
or author involvement with organization(s) with financial
interest in the subject matter.
Role of the funding source
The study sponsor, AlphaNet, had no role in the study
design, data collection, analysis or interpretation, writing
of the manuscript or decision to submit it for publication.
Supported by AlphaNet, Inc. and by the National Institute of
Health (grant K01 HL084675) to M.C.
Acknowledgements
To John Walsh from the Alpha-1 Foundation, Bonnie Boyd
and Rosemarie Carillo from AlphaNet and to all AlphaNet
Coordinators: Terry Young, Gayle Allison, Roger Bray, Dick
Bueker, Patti Brown, Victoria Cameron, Robert Campbell,
Shirley Dennis, Joyce Finch, Phil Freeman, Kathy Haduck,
Randy Harwell, Pat MacInnes, Darrel Nall, Diana Patterson,
Mary Pierce, Judy Rose, Sandy Singleton, Kathleen Sivesind,
Marta Strock, Kay Kinsel Swift, Doug Turley, Liz Veronda and
Fred Walsh.
Exacerbations in alpha-1 antitrypsin deficiency 1539References
1. Global Initiative for Chronic Obstructive Lung Disease. Global
strategy for the diagnosis, management, and prevention of
chronic obstructive lung disease (GOLD). Available at: www.
goldcopd.org; 2006 [accessed 7.17.07].
2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA.
Relationship between exacerbation frequency and lung func-
tion decline in chronic obstructive pulmonary disease. Thorax
2002 Oct;57(10):847e52.
3. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ,
Wedzicha JA. Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2000 May;161(5):1608e13.
4. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL,
Masa F, et al. Effect of exacerbations on quality of life in
patients with chronic obstructive pulmonary disease: a 2 year
follow up study. Thorax 2004 May;59(5):387e95.
5. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ,
Wedzicha JA. Effect of exacerbation on quality of life in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 1998 May;157(5 Pt 1):1418e22.
6. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW,
Menzin J. Assessment of the economic burden of COPD in the
U.S.: a review and synthesis of the literature. COPD 2006 Dec;
3(4):211e8.
7. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the
diagnosis of symptomatic patients with alpha1-antitrypsin defi-
ciency between 1968 and 2003. Chest 2005 Sep;128(3):1179e86.
8. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K,
Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency:
a continuing problem. Chest 2005 Oct;128(4):1989e94.
9. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence
for excessive bronchial inflammation during an acute exacer-
bation of chronic obstructive pulmonary disease in patients
with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit
Care Med 1999 Dec;160(6):1968e75.
10. McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML,
Schluchter MD, et al. Baseline characteristics of enrollees in
the National Heart, Lung and Blood Institute Registry of alpha
1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency
Registry Study Group. Chest 1997 Feb;111(2):394e403.
11. Needham M, Stockley RA. Exacerbations in {alpha}1-antitrypsin
deficiency. Eur Respir J 2005 Jun;25(6):992e1000.
12. American Thoracic Society/European Respiratory Society
Statement. Standards for the diagnosis and management of
individuals with alpha-1 antitrypsin deficiency. Am J Respir
Crit Care Med 2003 Oct 1;168(7):818e900.
13. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of
augmentation therapy on bronchial inflammation in alpha1-
antitrypsin deficiency. Am J Respir Crit Care Med 2002 Jun 1;
165(11):1494e8.14. Lieberman J. Augmentation therapy reduces frequency of lung
infections in antitrypsin deficiency: a new hypothesis with
supporting data. Chest 2000 Nov;118(5):1480e5.
15. Campos MA, Alazemi S, Zhang G, Sandhaus RA, Wanner A.
Influenza vaccination in subjects with alpha1-antitrypsin defi-
ciency. Chest 2008 Jan;133(1):49e55.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-
complete measure of health status for chronic airflow limita-
tion. The St. George’s Respiratory Questionnaire. Am Rev
Respir Dis 1992 Jun;145(6):1321e7.
17. Ware JE, Snow KK, Kosinski M. SF-36 health survey: manual and
interpretation guide. Lincoln, RI: QualityMetric Incorporated;
2002.
18. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES,
Harding GK, Nelson NA. Antibiotic therapy in exacerbations of
chronic obstructive pulmonary disease. Ann Intern Med 1987
Feb;106(2):196e204.
19. Rodriguez-Roisin R. Toward a consensus definition for COPD
exacerbations. Chest 2000 May;117(5 Suppl. 2):398Se401S.
20. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A,
Kok-Jensen A, et al. Does alpha1-antitrypsin augmentation
therapy slow the annual decline in FEV1 in patients with severe
hereditary alpha1-antitrypsin deficiency? Wissenschaftliche
Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen
(WATL) alpha1-AT study group. Eur Respir J 1997 Oct;10(10):
2260e3.
21. Survival and FEV1 decline in individuals with severe deficiency
of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency
Registry Study Group. Am J Respir Crit Care Med 1998 Jul;
158(1):49e59.
22. Vijayasaratha K, Stockley RA. Reported and unreported exac-
erbations of COPD: analysis by diary cards. Chest 2008 Jan;
133(1):34e41.
23. Dirksen A, Piitulainen E, Parr DG, Deng C,Wencker M, Shaker SB,
et al. Exploring the role of CT densitometry: a randomised study
of augmentation therapy in alpha-1 antitrypsin deficiency. Eur
Respir J, doi:10.1183/09031936.00159408.
24. Aventis Behring L. Zemaira package insert [updated 2003;
cited]. Available from: http://www.fda.gov/cber/products/
zemaira.htm; 2003.
25. Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM,
Wittes JT, et al. Replacement therapy for alpha 1-antitrypsin
deficiency associated with emphysema. N Engl J Med 1987 Apr
23;316(17):1055e62.
26. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG.
Biochemical efficacy and safety of monthly augmentation
therapy for alpha 1-antitrypsin deficiency. JAMA 1988 Sep 2;
260(9):1259e64.
27. Soy D, de la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M.
Alpha-1-antitrypsin deficiency: optimal therapeutic regimen
based on population pharmacokinetics. Thorax 2006 Dec;
61(12):1059e64.
